New Novartis drug cuts heart failure mortality, hospital admission A new drug by Novartis can reduce deaths and hospital admissions due to heart failure by 20 percent. Novartis is hoping that the drug will rejuvenate the company as its Diovan blood pressure pill is facing stiff competition from generic medicines. by Aaron Mamiit
Healthy Living/Wellness Will gene therapy be the answer to heart failure? Trial in London starts by Rhodi Lee
Healthy Living/Wellness Cytori stem-cell trials halted, investigators remain hopeful despite plummeting stock by Linda Nguyen
Healthy Living/Wellness FDA approves Boston Scientific's implantable defibrillators, heart failure devices by Lori Sandoval
Healthy Living/Wellness Early trial results of heart drug suggests Novartis has a winner on its hands by Tabitha Laffernis
Healthy Living/Wellness Traffic pollution may alter structure of the heart; promote heart failure by Tabitha Laffernis